Evidence map›Paper›PMID 27789809›Full record

ArticleAmerican journal of men's health2017

Eclipsed by the Prostate: Expanding Testicular Cancer Scholarship Through Years of Potential Life Lost and Economic Productivity.

Michael J Rovito

Abstract read
In one paragraph

Article in American journal of men's health, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Michael J Rovito1 University of Central Florida, Orlando, FL, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Men's health has been generalized as prostate cancer (PCa) with a supporting cast of other health issues, such as testicular cancer (TCa). As a result, research and scholarship in these supporting topical areas may not receive appropriate attention.This may possibly lead to disease burden indicators failing to comprehensively assess overall affect from a specific outcome within the population. The following commentary provides an example of years of potential life lost (YPLL) and economic productivity as it relates to TCa to encourage diversity in male health research and scholarship topical areas. Overall incidence and mortality rates overwhelmingly support a disparate burden from PCa as compared to other male-specific outcomes, specifically, TCa. When factoring in YPLL and lost economic activity as a result of early death, that disparity essentially dissipates. This discussion will provide an alternative disposition on how males are affected by PCa and TCa. Although PCa has much larger mortality and incidence rates compared to TCa, the amount of life a man potentially lo ses (nearly quadrupled) if he would die of TCa as compared to PCa assists in balancing out the disparate aforementioned burden. Suggestions are offered to encourage scholarship attention equity as well as implications for future research in the field.

Indexed as

EfficiencyFellowships and ScholarshipsLife ExpectancyProstatic NeoplasmsTesticular NeoplasmsHealth Status DisparitiesHumansMaleMedical OncologyResearchhealth inequality/disparityprostate cancerresearchtesticular cancer

Identifiers

PMID27789809
PMCPMC5675244

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.